Pilot study of transarterial chemoembolization with pirarubicin and amiodarone for unresectable hepatocellular carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 32, Issue 3, 2009, Pages 238-244

  Guiu, Boris ^a,b   Colin, Cédric ^b   Cercueil, Jean Pierre ^a   Loffroy, Romaric ^a   Guiu, Séverine ^c   Ferrant, Emmanuelle ^c   Jouve, Jean Louis ^b   Bonnetain, Franck ^c,d   Boulin, Mathieu ^a   Ghiringhelli, François ^c,d   Minello, Anne ^b   Hillon, Patrick ^b   Bedenne, Laurent ^b   Krause, Denis ^a   Chauffert, Bruno ^c,d  

^a HÔPITAL DU BOCAGE   (France)

^b University Hospital le Bocage   (France)

^c Georges François Leclerc Anticancer Center   (Canada)

^d UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Amiodarone; Hepatocellular carcinoma; Pirarubicin; Transarterial chemoembolization

Indexed keywords

AMIODARONE; CURASPON; GELATIN SPONGE; IODINATED POPPYSEED OIL; LIPIODOL ULTRAFLUIDE; PIRARUBICIN; THEPRUBICINE; UNCLASSIFIED DRUG;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; ASCITES; BLEEDING; BLOOD TOXICITY; BRADYCARDIA; CANCER LOCALIZATION; CANCER MORTALITY; CHEMOEMBOLIZATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERANCE; DRUG UPTAKE; ESOPHAGUS VARICES; ESOPHAGUS VARICES BLEEDING; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAZARD RATIO; HEPATIC ARTERY THROMBOSIS; HUMAN; INFECTION; INOPERABLE CANCER; INTESTINE PERFORATION; ISCHEMIC CHOLECYSTITIS; LEUKOPENIA; LIVER CELL CARCINOMA; LOG RANK TEST; MALE; MULTIPLE CANCER; NEUTROPENIA; OVERALL SURVIVAL; PILOT STUDY; POSTEMBOLIZATION SYNDROME; PROGNOSIS; PROGRESSION FREE SURVIVAL; SCORING SYSTEM; SEPSIS; STOMACH ULCER; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; AMIODARONE; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DOXORUBICIN; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IODIZED OIL; LIVER NEOPLASMS; MALE; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 67749099831     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181845529     Document Type: Article

References (52)

1. Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127:S5-S16.
2. Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153-156.
3. Sangiovanni A, Del Ninno E, Fasani P, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology. 2004;126:1005-1014.
4. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430.
5. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology. 2004;127:S179-S188.
6. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemo-embolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002; 359:1734-1739.
7. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164-1171.
8. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429-442.
9. Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46:474-481.
10. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med. 1995;332:1256-1261.
11. Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology. 1998;27:1578-1583.
12. Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol. 1998;29:129-134.
13. Geschwind JF, Ramsey DE, Choti MA, et al. Chemoembolization of hepatocellular carcinoma: results of a meta analysis. Am J Clin Oncol. 2003;26: 344-349.
14. Dhingra K, Frye D, Newman RA, et al. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. Clin Cancer Res. 1995;1:691-697.
15. Scheithauer W, Samonigg H, Depisch D, et al. Pirarubicin (4′-o-tetrahydro-pyranil-adriamycin) for treatment of advanced breast cancer. A clinical phase II study. Invest New Drugs. 1990;8:207-210.
16. Cercueil JP, Ferrant E, Isambert N, et al. Sustained clinical response of large hepatocellular carcinoma after chemoembolization with pirarubicin, amioda-rone and lipiodol. Gastroenterol Clin Biol. 2004;28:1281-1283.
17. Ueno K, Miyazono N, Inoue H, et al. Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma: evaluation of three kinds of regimens and analysis of prognostic factors. Cancer. 2000;88:1574-1581.
18. Inoue H, Miyazono N, Kanetsuki I, et al. Anticancer and side effect of arterial subsegmental chemoembolization using cisplatinum/pirarubicin lipiodol suspension (CTLS) for hepatocellular carcinoma [in Japanese]. Gan To Kagaku Ryoho. 1993;20:1973-1976.
19. Izumi N, Goto Y. A clinical trial of transarterial chemoembolization for hepatocellular carcinoma using 4′-o-tetrahydropyranyladriamycin. Gan To Kagaku Ryoho. 1990;17:1303-1307.
20. Favoulet P, Cercueil JP, Faure P, et al. Increased cytotoxicity and stability of Lipiodol-pirarubicin emulsion compared to classical doxorubicin-Lipiodol: potential advantage for chemoembolization of unresectable hepatocellular carcinoma. Anticancer Drugs. 2001;12:801-806.
21. Munck JN, Riggi M, Rougier P, et al. Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumor model. Cancer Res. 1993;53: 1550-1554.
22. Robert J, Monnier A, Poutignat N, et al. A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients. Cancer Chemother Pharmacol. 1991;29:75-79.
23. Tapiero H, Munck JN, Fourcade A. Relationship between the intracellular accumulation of anthracyclines and effectiveness in vitro and in vivo. Drugs Exp Clin Res. 1986;12:257-264.
24. Minemura M, Tanimura H, Tabor E. Overexpression of multidrug resistance genes MDR1 and cMOAT in human hepatocellular carcinoma and hepatoblastoma cell lines. Int J Oncol. 1999;15:559-563.
25. Chauffert B, Martin M, Hammann A, et al. Amiodarone-induced enhancement of doxorubicin and 4′-deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo. Cancer Res. 1986;46:825-830.
26. Yi SW, Kim YH, Kwon IC, et al. Stable lipiodolized emulsions for hepatoma targeting and treatment by transcatheter arterial chemoembolization. J Control Release. 1998;50:135-143.
27. Gates J, Hartnell GG, Stuart KE, et al. Chemoembolization of hepatic neoplasms: safety, complications, and when to worry. Radiographics. 1999; 19:399-414.
28. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208 -1236.
29. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30:6-25.
30. Liapi E, Geschwind JF. Transcatheter and ablative therapeutic approaches for solid malignancies. J Clin Oncol. 2007;25:978-986.
31. Favoulet P, Benoit L, Osmak L, et al. Prevention of peritoneal carcinomatosis from colon cancer cell seeding using a pirarubicin solution in rats and nude mice. World J Surg. 2004;28:451-456.
32. Vetter D, Wenger JJ, Bergier JM, et al. Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: results of a western comparative study in 60 patients. Hepatology. 1991;13:427-433.
33. Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 2006;131:461-469.
34. Dumortier J, Chapuis F, Borson O, et al. Unresectable hepatocellular carcinoma: survival and prognostic factors after lipiodol chemoembolisation in 89 patients. Dig Liver Dis. 2006;38:125-133.
35. Mondazzi L, Bottelli R, Brambilla G, et al. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology. 1994;19:1115-1123.
36. Biselli M, Andreone P, Gramenzi A, et al. Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case-controlled study. Clin Gastroenterol Hepatol. 2005;3:918-925.
37. Farinati F, Rinaldi M, Gianni S, et al. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer. 2000;89:2266-2273.
38. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol. 2005;40:225-235.
39. Martins A, Cortez-Pinto H, Marques-Vidal P, et al. Treatment and prognostic factors in patients with hepatocellular carcinoma. Liver Int. 2006;26:680-687.
40. Testa R, Testa E, Giannini E, et al. Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment. Aliment Pharmacol Ther. 2003;17:1563-1569.
41. Vogl TJ, Trapp M, Schroeder H, et al. Transarterial chemoembolization for hepatocellular carcinoma: volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success-results from a liver transplantation center. Radiology. 2000;214:349-357.
42. Lee JK, Chung YH, Song BC, et al. Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization. J Gastroenterol Hepatol. 2002;17:52-58.
43. Poyanli A, Rozanes I, Acunas B, et al. Palliative treatment of hepatocellular carcinoma by chemoembolization. Acta Radiol. 2001;42:602-607.
44. Stefanini GF, Amorati P, Biselli M, et al. Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience. Cancer. 1995;75:2427-2434.
45. Llad L, Virgili J, Figueras J, et al. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer. 2000;88:50-57.
46. Calvet X, Bruix J, Gines P, et al. Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. Hepatology. 1990;12:753-760.
47. Hsieh MY, Chang WY, Wang LY, et al. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization and analysis of prognostic factors. Cancer Chemother Pharmacol. 1992;31(suppl):S82-S85.
48. Ikeda K, Kumada H, Saitoh S, et al. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. An analysis by the Cox proportional hazard model. Cancer. 1991;68:2150- 2154.
49. Savastano S, Miotto D, Casarrubea G, et al. Transcatheter arterial chemoem-bolization for hepatocellular carcinoma in patients with Child's grade A or B cirrhosis: a multivariate analysis of prognostic factors. J Clin Gastroenterol. 1999;28:334-340.
50. Farinati F, De Maria N, Marafin C, et al. Unresectable hepatocellular carcinoma in cirrhosis: survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolization. Dig Dis Sci. 1996;41: 2332-2339.
51. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). ASCO 2007; Chicago, IL.
52. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24: 4293-4300.